KRAS and familial pancreatic carcinoma: Goodwin et al. [84] conducted CRISPR knockout screening in pancreatic cancer cells harboring KRAS mutations and identified a number of functionally diverse genes whose inhibition can enhance the growth-inhibiting effect of CDK4/6 inhibitors.